VEGFR-3-IN-1

• CAT Number: I045382
• CAS Number: 2756668-73-0
• Molecular Formula: C29H29ClF3N7OS
• Molecular Weight: 616.10
• Purity: ≥95%
• Synonyms: N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[6-[4-(4-methylpiperazin-1-yl)phenyl]thieno[2,3-d]pyrimidin-4-yl]piperazine-1-carboxamide
• InChI: InChI=1S/C29H29ClF3N7OS/c1-37-8-10-38(11-9-37)21-5-2-19(3-6-21)25-17-22-26(34-18-35-27(22)42-25)39-12-14-40(15-13-39)28(41)36-20-4-7-24(30)23(16-20)29(31,32)33/h2-7,16-18H,8-15H2,1H3,(H,36,41)
• InChIKey: ZYZUOYYVHYGMDE-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC=C(C=C2)C3=CC4=C(N=CN=C4S3)N5CCN(CC5)C(=O)NC6=CC(=C(C=C6)Cl)C(F)(F)F

VEGFR-3-IN-1 (Cat No.: I045382) is a selective small-molecule inhibitor targeting vascular endothelial growth factor receptor 3 (VEGFR-3), a receptor tyrosine kinase primarily involved in lymphangiogenesis and metastatic tumor spread. By blocking VEGFR-3 signaling, this inhibitor disrupts lymphatic vessel formation and impairs the growth and dissemination of tumors reliant on lymphatic pathways. VEGFR-3-IN-1 is commonly used in preclinical research to investigate the role of VEGFR-3 in cancer biology, inflammation, and lymphatic disorders, and to evaluate anti-angiogenic and anti-metastatic therapeutic strategies.

Reference

[1]. Li Y, Yang G, et al. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021;64(16):12022-12048.
[Content Brief]